Formulation and Evaluation of Mesalazine Nanoemulsion for Rectal Administration
نویسندگان
1 Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq
2 Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq
doi
10.22052/JNS.2026.02.044چکیده
Mesalazine (MSZ) is an anti-inflammatory medication used to treat and maintain relief in mild to severe ulcerative colitis (UC) or Crohn’s disease (CD). MSZ has been demonstrated to be an effective scavenger of reactive oxygen species, which significantly contribute to the pathogenesis of inflammatory bowel disease; to suppress natural killer cell activity; to inhibit antibody synthesis; to block cyclooxygenase and lipoxygenase pathways; and to impair neutrophil function. To prepare and stabilize mesalazine and increase intraluminal colonic concentrations. We determined the solubility of MSZ in different oils and surfactants. Based on the solubility results, we constructed a phase diagram and prepared a nanoemulsion with various oil types and ratios (vitamin E and imwitour 308).Smix using Cremophor EL and propylene glycol. After successful nanoemulsion preparation, an in vivo study was done. Nanoemulsion characteristics were evaluated by particle size (PS), polydispersity index (PDI), and drug content. In vitro drug release was compared by assessing changes resulting from variations in concentration and oil type. FTIR, PXRD, and TEM were used to further evaluate the optimum formula. the particle size of the formula ranged from 6nm to 574nm. The optimized formulation M11 and M20 was further evaluated for morphological characteristics. It revealed the presence of a spherical droplet. Fourier-transform infrared spectroscopy (FTIR) indicated no chemical interactions.
